Your new post is loading...
Northwestern University scientists have developed a new family of compounds that could slow the progression of Parkinson’s disease.
Parkinson’s, the second most common neurodegenerative disease, is caused by the death of dopamine neurons, resulting in tremors, rigidity and difficulty moving. Current treatments target the symptoms but do not slow the progression of the disease.
The compounds work by blocking calcium. The compounds target and shut a relatively rare membrane protein that allows calcium to flood into dopamine neurons.
